Safety Signal Identification for Risankizumab-rzaa in the Sentinel Distributed Database Using Self-Controlled and Active Comparator Study Designs

Risankizumab-rzaa, FDA-approved in 2019, is an IL-23 inhibitor currently indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This study was initiated to detect new potential safety signals following the initiation of risankizumab-rzaa using both self-controlled risk interval (SCRI) or active comparator (AC) designs. The findings are presented in this poster.